Vivatides Therapeutics develops RNA treatments to help improve patients' lives using biotechnology research.
Vivatides Therapeutics has raised $54.0M in total funding. The most recent round was Series A. The last funding was announced in April 2026.
Vivatides Therapeutics's investors include Qiming Venture Partners, Highlight Capital, Apricot Capital, TF Capital, Xingze Capital.
Vivatides Therapeutics is headquartered in Woburn, United States.
Vivatides Therapeutics develops RNA treatments to help improve patients' lives using biotechnology research.
Vivatides Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vivatides Therapeutics — Funding & Investors." VCBacked, April 10, 2026, https://www.vcbacked.co/company/vivatides-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). Vivatides Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/vivatides-therapeutics
{{cite web |title=Vivatides Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/vivatides-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated